Chemomab Therapeutics Ltd. (NASDAQ:CMMB) Sees Significant Increase in Short Interest

Chemomab Therapeutics Ltd. (NASDAQ:CMMB) was the target of a significant increase in short interest in the month of February. As of February 28th, there was short interest totalling 389,900 shares, an increase of 1,230.7% from the February 13th total of 29,300 shares. Approximately 2.4% of the shares of the stock are sold short. Based on an average trading volume of 336,300 shares, the days-to-cover ratio is currently 1.2 days.

Analyst Ratings Changes

CMMB has been the topic of a number of recent analyst reports. Oppenheimer reissued an “outperform” rating and set a $11.00 price target (down from $13.00) on shares of Chemomab Therapeutics in a report on Friday, November 15th. Maxim Group boosted their price objective on Chemomab Therapeutics from $4.00 to $7.00 and gave the stock a “buy” rating in a research note on Thursday, February 20th.

Chemomab Therapeutics Stock Up 4.4 %

Shares of NASDAQ:CMMB opened at $1.42 on Thursday. Chemomab Therapeutics has a 52-week low of $0.58 and a 52-week high of $2.55. The stock has a market cap of $20.39 million, a P/E ratio of -1.42 and a beta of 0.54. The business’s 50 day moving average is $1.90 and its 200 day moving average is $1.75.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Virtu Financial LLC purchased a new stake in Chemomab Therapeutics during the fourth quarter worth $26,000. XTX Topco Ltd grew its position in Chemomab Therapeutics by 63.8% during the 4th quarter. XTX Topco Ltd now owns 24,929 shares of the company’s stock worth $45,000 after purchasing an additional 9,706 shares during the period. Finally, Sphera Funds Management LTD. acquired a new stake in shares of Chemomab Therapeutics during the 3rd quarter valued at about $1,907,000. Institutional investors own 46.05% of the company’s stock.

About Chemomab Therapeutics

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).